"10.1371_journal.pone.0007758","plos one","2009-11-18T00:00:00Z","Nabarun Dasgupta; Kenneth D Mandl; John S Brownstein","Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, Unites States of America; Children's Hospital Informatics Program at Harvardâ€“Massachusetts Institute of Technology, Division of Health Sciences and Technology, Boston, Massachusetts, United States of America; Division of Emergency Medicine, Children's Hospital Boston, Boston, Massachusetts, United States of America; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America","Conceived and designed the experiments: ND JSB. Performed the experiments: ND JSB. Analyzed the data: ND JSB. Contributed reagents/materials/analysis tools: ND JSB. Wrote the paper: ND KDM JSB.","We acknowledge the consulting arrangements below. In the past 3 years, Dasgupta has had one-time consultant arrangements with opioid manufacturers on methodological issues related to post-marketing surveillance: King, Neuromed, Pain Therapeutics, Schering-Plough. He currently is on risk management advisory board for Cephalon. Dasgupta is a consultant for the RADARS System (Rocky Mountain Poison & Drug Center, Denver Health), a non-profit public health surveillance system. Brownstein consults on the topic of public health surveillance surveillance of opioid abuse for Inflexxion (Newton, MA), King Pharmaceuticals and Cephalon (via advisory board). Mandl has no competing interests to report.","2009","11","Nabarun Dasgupta","ND",3,FALSE,2,2,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
